NCT00401778View on ClinicalTrials.gov

Trial of RAD001 in Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Lung Cancer
Interventions
DRUG

RAD001

Patients will be assigned to one of three treatment arms with RAD001 doses of 5, and 10 mg/day for 21-28 days sequentially taken orally in tablet form.

Trial Locations (1)

30322

Emory University Winship Cancer Institute, Atlanta

All Listed Sponsors
lead

Emory University

OTHER

NCT00401778 - Trial of RAD001 in Patients With Operable Non-Small Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter